

VOL 20, No 4

FEBRUARY 15, 2002

# JOURNAL OF CLINICAL ONCOLOGY

Official Journal of the American  
Society of Clinical Oncology

WESTON LIBRARY

FEB 22 2002

J5/120 CLINICAL SCIENCE CENTER  
600 HIGHLAND AVE MADISON WI 53792

JCO's Manuscript Submission Requirements have changed!

Please see our NEW information for Contributors.

**ASCO**  <sup>TM</sup>

[www.asco.org](http://www.asco.org)

Amgen Exhibit 1026  
Amgen v. BMS

Lippincott Williams & Wilkins

# JOURNAL OF CLINICAL ONCOLOGY

*The Official Journal of the American Society of Clinical Oncology*

*Journal of Clinical Oncology* (ISSN 0732-183X) is published 24 times a year, twice monthly, by Lippincott Williams & Wilkins, 16522 Hunters Green Parkway, Hagerstown, MD 21740-2116. Periodical postage is paid at Hagerstown, MD, and at additional mailing offices.

**POSTMASTER:** ASCO members send change of address to American Society of Clinical Oncology, 1900 Duke Street, Suite 200, Alexandria, VA 22314. Non-members send change of address to *Journal of Clinical Oncology*, c/o Lippincott Williams & Wilkins, PO Box 1550, Hagerstown, MD 21740.

**Editorial correspondence** should be addressed to Daniel G. Haller, MD, *Journal of Clinical Oncology*, 1900 Duke Street, Suite 200, Alexandria, VA 22314. Telephone: (703) 797-1900; FAX: (703) 684-8720. Email: jco@asco.org. Internet: <http://www.jco.org>

American Society of Clinical Oncology-related questions should be addressed to ASCO, 1900 Duke Street, Suite 200, Alexandria, VA 22314. Telephone: (703) 299-0150; FAX: (703) 299-1044. Email: [asco@asco.org](mailto:asco@asco.org). Internet: <http://www.asco.org>

**Correspondence** regarding subscriptions or change of address should be directed to *Journal of Clinical Oncology*, Lippincott Williams & Wilkins, 16522 Hunters Green Parkway, Hagerstown, MD 21740-2116.

**Japan:** Orders should be placed through LWW Igaku-Shoin Ltd, 3-23-14 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan. Telephone: 3-5689-5400; FAX: 3-5689-2760. Email: [yhirano@lwwis.co.jp](mailto:yhirano@lwwis.co.jp). **India, Pakistan, Sri Lanka, Bangladesh, Nepal:** Orders should be placed through Globe Publication Pvt Ltd, B-13, 3rd Floor, A Block, Shopping Complex, Naraina Vihar, Ring Road, New Delhi 110028, India. Telephone: 11-5790212; FAX: 11-5798876. Email: [jaideep.globe@access.net.in](mailto:jaideep.globe@access.net.in).

**Change of address notices**, including both the old and new addresses of the subscriber and the mailing label, should be sent at least one month in advance.

**Customer Service:** 1-877-734-3512

**Yearly subscription rates:** United States and possessions: individuals, \$325.00; institutions, \$452.00; students and residents, \$127.00; single issues, \$25.00. All other countries: individuals, \$496.00; institutions, \$623.00; students and residents, \$193.00; single issues, \$25.00. To receive student/resident rate, orders must be accompanied by name of affiliated institution, date of term, and the *signature* of program/residency coordinator on institution letterhead. Orders will be billed at individual rate until proof of status is received. Publication Mail Agreement Number 863289.

Prices are subject to change without notice. Current prices are in effect for back volumes and back issues. Single issues, both current and back, exist in limited quantities and are offered for sale subject to availability. Back issues sold in conjunction with a subscription are on a prorated basis. *2001 bound volume price:* \$140.00; \$165.00 for international orders. To purchase a 2001 bound volume, customer must be a subscriber for 2001.

Copyright © 2002 by American Society of Clinical Oncology. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means now or hereafter known, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the Publisher. Printed in the United States of America.

Correspondence regarding permission to reprint all or part of any article published in this journal should be addressed to Journals Permission Department, Lippincott Williams & Wilkins, 351 West Camden Street, Baltimore, MD 21201-2436.

The appearance of the code at the bottom of the first page of an article in this journal indicates the copyright owner's consent that copies of the article may be made for personal or internal use, or for the personal or internal use of specific clients, for those registered with the Copyright Clearance Center, Inc. (222 Rosewood Drive, Danvers, MA 01923; (978) 750-8400; [www.copyright.com](http://www.copyright.com)). This consent is given on the condition that the copier pay the stated per-copy fee for that article through the Copyright Clearance Center, Inc. for copying beyond that permitted by Sections 107 or 108 of the US Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. Absence of the code indicates that the material may not be processed through the Copyright Clearance Center, Inc.

**Advertising representative:** Martha McGarity, Lippincott Williams & Wilkins, 345 Hudson Street, 16th Floor, New York, NY 10014. Telephone: 212-886-1350.

The ideas and opinions expressed in the *Journal of Clinical Oncology* do not necessarily reflect those of the American Society of Clinical Oncology, the Editor or the Publisher. Publication of an advertisement or other product mention in the *Journal of Clinical Oncology* should not be construed as an endorsement of the product or the manufacturer's claims. Readers are encouraged to contact the manufacturer with any questions about the features or limitations of the products mentioned. Neither the American Society of Clinical Oncology nor the Publisher assumes any responsibility for any injury and/or damage to persons or property arising out of or related to any use of the material contained in this periodical. The reader is advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify the dosage, the method and duration of administration, or contraindications. It is the responsibility of the treating physician or other health care professional, relying on independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient.

Every effort has been made to check generic and trade names, and to verify drug doses. The ultimate responsibility, however, lies with the prescribing physician. Please convey any errors to the Editor.

# Journal of Clinical Oncology

*The Official Journal of the American Society of Clinical Oncology*

Vol 20, No 4

February 15, 2002

## CONTENTS

### EDITORIALS

- Clinical Link Between p53 and Angiogenesis in Lung Cancer** ..... Sarah J. Freemantle and Ethan Dmitrovsky 883
- Statistical Prediction Models, Artificial Neural Networks, and the Sophism "I Am a Patient, Not a Statistic"** ..... Michael Kattan 885
- Cancer Survivorship Research: The Best Is Yet to Come** ..... David J. Vaughn and Anna T. Meadows 888
- Chemoradiation for Locally Advanced Cervical Cancer: Does It Help?** ... Peter G. Rose and Brian N. Bundy 891
- An Evolving Role for Oral Fluoropyrimidine Drugs** ..... Robert B. Diasio 894
- Microsatellite Instability Phenotype of Tumors: Genotyping or Immunohistochemistry? The Jury Is Still Out** ..... Albert de la Chapelle 897

### ORIGINAL REPORTS

#### *Lung Cancer*

- Aberrant p53 Expression Correlates With Expression of Vascular Endothelial Growth Factor mRNA and Interleukin-8 mRNA and Neoangiogenesis in Non-Small-Cell Lung Cancer** ... Ang Yuan, Chong-Jen Yu, Kwen-Tay Luh, Sow-Hsong Kuo, Yung-Chie Lee, and Pan-Chyr Yang 900
- Screening for Lung Cancer With Low-Dose Helical Computed Tomography: Anti-Lung Cancer Association Project** ..... Tomotaka Sobue, Noriyuki Moriyama, Masahiro Kaneko, Masahiko Kusumoto, Toshiaki Kobayashi, Ryosuke Tsuchiya, Ryutaro Kakinuma, Hironobu Ohmatsu, Kanji Nagai, Hiroyuki Nishiyama, Eisuke Matsui, and Kenji Eguchi 911
- Novel Artificial Neural Network for Early Detection of Prostate Cancer** ..... Bob Djavan, Mesut Remzi, Alexandre Zlotta, Christian Seitz, Peter Snow, and Michael Marberger 921

*Journal of Clinical Oncology* (ISSN 0732-183X) is published 24 times a year, twice monthly, by Lippincott Williams & Wilkins, 351 West Camden Street, Baltimore, MD 21201-2436. Periodicals postage paid at Hagerstown, MD, and at additional mailing offices. The GST number for Canadian Subscribers is 895524239.

Editorial correspondence should be addressed to Daniel G. Haller, MD, *Journal of Clinical Oncology*, 1900 Duke St, Suite 200, Alexandria, VA 22314. Telephone: (703) 797-1900; FAX: (703) 684-8720. Email: jco@asco.org. Internet: <http://www.jco.org>

**POSTMASTER:** ASCO members send change of address to American Society of Clinical Oncology, 1900 Duke St, Suite 200, Alexandria, VA 22314. Non-members send change of address to *Journal of Clinical Oncology*, c/o Lippincott Williams & Wilkins, PO Box 1550, Hagerstown, MD 21740.

Yearly subscription rates: United States and possessions: individual, \$325.00; institution, \$452.00; single issues, \$25.00. All other countries: individual, \$496.00; institution, \$623.00; single issue, \$25.00. Student and resident: United States and possessions: \$127.00, all other countries: \$193.00. To receive student/resident rate, orders must be accompanied by name of affiliated institution, date of term, and the signature of program/residency coordinator on institution letterhead. Orders will be billed at individual rate until proof of status is received. Current prices are in effect for back volumes and back issues. Back issues sold in conjunction with a subscription rate are on a prorated basis. Subscriptions are accepted on a calendar year basis. Prices are subject to change without notice. Single issues, both current and back, exist in limited quantities and are offered for sale subject to availability. Publication Mail Agreement Number 863289.

|                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                 |      |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| <b>Postchemotherapy Ejaculatory Azoospermia: Fatherhood With Sperm From Testis Tissue With Intracytoplasmic Sperm Injection .....</b>                                                                                                  | <i>M.N. Damani, V. Masters, M.V. Meng, C. Burgess, P. Turek, and R.D. Oates</i>                                                                                                                                                                                                                                 | 930  |
| <b>Phase II Trial of Weekly Paclitaxel in Patients With Previously Treated Advanced Urothelial Cancer</b>                                                                                                                              | <i>David J. Vaughn, Catherine M. Broome, Maha Hussain, John C. Gutheil, and Avi B. Markowitz</i>                                                                                                                                                                                                                | 937  |
| <b>Adrenocortical Carcinoma: Clinical, Morphologic, and Molecular Characterization</b>                                                                                                                                                 | <i>Alexander Stojadinovic, Ronald A. Ghossein, Axel Hoos, Aviram Nissan, David Marshall, Maria Dudas, Carlos Cordon-Cardo, David P. Jaques, and Murray F. Brennan</i>                                                                                                                                           | 941  |
| <b>Validation Study of the Accuracy of a Postoperative Nomogram for Recurrence After Radical Prostatectomy for Localized Prostate Cancer ....</b>                                                                                      | <i>Markus Graefen, Pierre I. Karakiewicz, Ilias Cagiannos, Eric Klein, Patrick A. Kupelian, David I. Quinn, Susan M. Henshall, John J. Grygiel, Robert L. Sutherland, Phillip D. Stricker, Jean de Kernion, Thomas Cangiano, Fritz H. Schröder, Mark F. Wildhagen, Peter T. Scardino, and Michael W. Kattan</i> | 951  |
| <b>Successful Adenovirus-Mediated Wild-Type p53 Gene Transfer in Patients With Bladder Cancer by Intravesical Vector Instillation .....</b>                                                                                            | <i>Jürgen Kuball, Shu Fen Wen, Joachim Leissner, Derek Atkins, Patricia Meinhardt, Erlinda Quijano, Heidrun Engler, Beth Hutchins, Daniel C. Maneval, Michael J. Grace, Mary Ann Fritz, Stefan Störkel, Joachim W. Thüroff, Christoph Huber, and Martin Schuler</i>                                             | 957  |
| <b>Gynecologic Oncology</b>                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                 |      |
| <b>Phase III Trial Comparing Radical Radiotherapy With and Without Cisplatin Chemotherapy in Patients With Advanced Squamous Cell Cancer of the Cervix .....</b>                                                                       | <i>R. Pearcey, M. Brundage, P. Drouin, J. Jeffrey, D. Johnston, H. Lukka, G. MacLean, L. Souhami, G. Stuart, and D. Tu</i>                                                                                                                                                                                      | 966  |
| <b>Increased Cyclooxygenase-2 Expression Is Associated With Chemotherapy Resistance and Poor Survival in Cervical Cancer Patients .....</b>                                                                                            | <i>G. Ferrandina, L. Lauriola, M.G. Distefano, G.F. Zannoni, M. Gessi, F. Legge, N. Maggiano, S. Mancuso, A. Capelli, G. Scambia, and F.O. Ranelletti</i>                                                                                                                                                       | 973  |
| <b>Epithelial Ovarian Cancer Metastasizing to the Brain: A Late Manifestation of the Disease With an Increasing Incidence .....</b>                                                                                                    | <i>Desiree F. Kolomainen, James M.G. Larkin, Mohammad Badran, Roger P. A'Hern, D. Michael King, Cyril Fisher, Jane E. Bridges, Peter R. Blake, Desmond P.J. Barton, John H. Shepherd, Stanley B. Kaye, and Martin E. Gore</i>                                                                                   | 982  |
| <b>Breast Cancer</b>                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                 |      |
| <b>Multicenter Phase II Study of a 28-Day Regimen of Orally Administered Eniluracil and Fluorouracil in the Treatment of Patients With Anthracycline- and Taxane-Resistant Advanced Breast Cancer</b>                                  | <i>Edgardo Rivera, Linda Sutton, Bruce Colwell, Mark Graham, Debra Frye, Matt Somerville, Heather S. Conklin, Chip McGuirt, Jeremy Levin, and Gabriel N. Hortobagyi</i>                                                                                                                                         | 987  |
| <b>BRCA1 and BRCA2 Mutation Frequency in Women Evaluated in a Breast Cancer Risk Evaluation Clinic</b>                                                                                                                                 | <i>Helen A. Shih, Fergus J. Couch, Katherine L. Nathanson, M. Anne Blackwood, Timothy R. Rebbeck, Katrina A. Armstrong, Kathleen Calzone, Jill Stopfer, Sheila Seal, Michael R. Stratton, and Barbara L. Weber</i>                                                                                              | 994  |
| <b>Clinical Relevance of Invasion Factors Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1 for Individualized Therapy Decisions in Primary Breast Cancer Is Greatest When Used in Combination .....</b> | <i>Nadia Harbeck, Ronald E. Kates, and Manfred Schmitt</i>                                                                                                                                                                                                                                                      | 1000 |

**Communication Between Physicians and Older Women With Localized Breast Cancer: Implications for Treatment and Patient Satisfaction** ..... Wenchi Liang, Caroline B. Burnett, Julia H. Rowland, Neal J. Meropol, Lynne Eggert, Yi-Ting Hwang, Rebecca A. Silliman, Jane C. Weeks, and Jeanne S. Mandelblatt 1008 

**Dietary Change After Breast Cancer: Extent, Predictors, and Relation With Psychological Distress** ..... Elizabeth Maunsell, Mélanie Drolet, Jacques Brisson, Jean Robert, and Luc Deschênes 1017

**Comparison of the Systemic and Intratumoral Effects of Tamoxifen and the Aromatase Inhibitor Vorozole in Postmenopausal Patients With Primary Breast Cancer** ..... Catherine L. Harper-Wynne, Nigel P.M. Sacks, Karyn Shenton, Fiona A. MacNeill, Paul Sauven, Ian J. Laidlaw, Zen Rayter, Stephanie Miall, Angela Howes, Janine Salter, Margaret J. Hills, Frances M. Lowe, Roger A'Hern, Nazar Nasiri, Debbie Doody, Jhangir Iqbal, and Mitchell Dowsett 1026

**Assessment of Coronary Heart Disease Morbidity and Mortality After Radiation Therapy for Early Breast Cancer** ..... Katherine A. Vallis, Melania Pintilie, Nelson Chong, Eric Holowaty, Pamela S. Douglas, Peter Kirkbride, and Andreas Wielgosz 1036

### *Gastrointestinal Cancer*

**Immunohistochemistry Versus Microsatellite Instability Testing in Phenotyping Colorectal Tumors** ..... Noralane M. Lindor, Lawrence J. Burgart, Olga Leontovich, Richard M. Goldberg, Julie M. Cunningham, Daniel J. Sargent, Catherine Walsh-Vockley, Gloria M. Petersen, Michael D. Walsh, Barbara A. Leggett, Joanne P. Young, Melissa A. Barker, Jeremy R. Jass, John Hopper, Steve Gallinger, Bharati Bapat, Mark Redston, and Stephen N. Thibodeau for the Cooperative Family Registry for Colon Cancer Studies 1043

**Prognostic Significance of Cytokeratin-20 Reverse Transcriptase Polymerase Chain Reaction in Lymph Nodes of Node-Negative Colorectal Cancer Patients** ..... Robert Rosenberg, Axel Hoos, James Mueller, Patricia Baier, Dominik Stricker, Martin Werner, Hjalmar Nekarda, and Jörg-Rüdiger Siewert 1049

**Role of Health-Related Quality of Life in Palliative Chemotherapy Treatment Decisions** ..... S.B. Detmar, M.J. Muller, J.H. Schornagel, L.D.V. Wever, and N.K. Aaronson 1056

### *CNS Tumors*

**Quantitatively Determined Survivin Expression Levels Are of Prognostic Value in Human Gliomas** ..... Arnab Chakravarti, Elizabeth Noll, Peter McL. Black, Daniel F. Finkelstein, Dianne M. Finkelstein, Nicholas J. Dyson, and Jay S. Loeffler 1063

### *Melanoma*

**Loss of MDA-7 Expression With Progression of Melanoma** ..... Julie A. Ellerhorst, Victor G. Prieto, Suhendan Ekmekcioglu, Lyle Broemeling, Sandra Yekell, Sunil Chada, and Elizabeth A. Grimm 1069

**Phase I Trial of Adoptive Immunotherapy With Cytolytic T Lymphocytes Immunized Against a Tyrosinase Epitope** .... Malcolm S. Mitchell, Denise Darrah, David Yeung, Samuel Halpern, Anne Wallace, Joseph Voland, Vicky Jones, and June Kan-Mitchell 1075

### *Hematologic Malignancies*

**Hodgkin's Disease in the Elderly: Improved Treatment Outcome With a Doxorubicin-Containing Regimen** ..... Colin D. Weekes, Julie M. Vose, Jim C. Lynch, Dennis D. Weisenburger, Philip J. Bierman, Timothy Greiner, Gregory Bociek, Charles Enke, Martin Bast, Wing C. Chan, and James O. Armitage for the Nebraska Lymphoma Study Group 1087 

|                                                                                                                                        |                                                                                                                                                                                               |      |
|----------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| <b>Minimal Residual Disease Tests Provide an Independent Predictor of Clinical Outcome in Adult Acute Lymphoblastic Leukemia .....</b> | <i>Florida Y. Mortuza, Mary Papaioannou, Ilidia M. Moreira, Luke A. Coyle, Paula Gameiro, Domenica Gandini, H. Grant Prentice, Anthony Goldstone, A. Victor Hoffbrand, and Letizia Foroni</i> | 1094 |
|----------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|

#### *Tumor Biology*

|                                                                                                                               |                                                                                                                                                                                         |      |
|-------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| <b>Determination of the Molecular Relationship Between Multiple Tumors Within One Patient Is of Clinical Importance .....</b> | <i>Joost R.M. van der Sijp, Jan P.A.M. van Meerbeeck, Alex P.W.M. Maat, Pieter E. Zondervan, Hein F.B.M. Sleddens, Albert N. van Geel, Alex M.M. Eggermont, and Winand N.M. Dinjens</i> | 1105 |
|-------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|

#### *Phase I and Pharmacokinetics*

|                                                                                             |                                                                                                                                                                                                                         |      |
|---------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| <b>Phase I Clinical and Pharmacologic Trial of Intravenous Estramustine Phosphate .....</b> | <i>Gary Hudes, Naomi Haas, Gwen Yeslow, Thomas Gillon, Per Olov Gunnarsson, Marianne Ellman, Orjan Nordle, Brigitta Eriksson, Langdon Miller, Laura Cisar, Michael Kopreski, Donatella Viaro, and Beryl Hartley-Asp</i> | 1115 |
|---------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|

### **REVIEW ARTICLE**

|                                                              |                                                             |      |
|--------------------------------------------------------------|-------------------------------------------------------------|------|
| <b>Weight Loss in Breast Cancer Patient Management .....</b> | <i>Rowan T. Chlebowski, Erin Aiello, and Anne McTiernan</i> | 1128 |
|--------------------------------------------------------------|-------------------------------------------------------------|------|

### **SPECIAL DEPARTMENTS**

|                             |  |      |
|-----------------------------|--|------|
| <b>Correspondence .....</b> |  | 1144 |
|-----------------------------|--|------|

**When the Mirror Doesn't Reflect It at All .....** *Stanley E. Order and Wayne Court*

• **In Reply .....** *Felix E. de Jongh, Jaap Verweij, and Alex Sparreboom*

**Mortality Associated With Irinotecan Plus Bolus Fluorouracil/Leucovorin .....** *Harry Bleiberg and Angelo Di Leo*

• **In Reply .....** *Mace L. Rothenberg, Neal J. Meropol, Elizabeth A. Poplin, Eric Van Cutsem, and Scott Wadler*

**Hypersensitivity Reactions to Oxaliplatin: Cross-Reactivity to Carboplatin and the Introduction of a Desensitization Schedule .....** *Lars Meyer, Torsten Zuberbier, Margitta Worm, Helmut Oettle, and Hanno Riess*

**Ovarian and Papillary-Serous Peritoneal Carcinoma: Pilot Study With Thalidomide .....** *N. Abramson, P.K. Stokes, Mathew Luke, Alan R. Marks, and Jeffrey M. Harris*

|                            |  |    |
|----------------------------|--|----|
| <b>Announcements .....</b> |  | B1 |
|----------------------------|--|----|

|                                           |  |     |
|-------------------------------------------|--|-----|
| <b>Information for Contributors .....</b> |  | A27 |
|-------------------------------------------|--|-----|

|                                |  |     |
|--------------------------------|--|-----|
| <b>Current Abstracts .....</b> |  | A24 |
|--------------------------------|--|-----|

|                             |  |     |
|-----------------------------|--|-----|
| <b>Books Received .....</b> |  | A41 |
|-----------------------------|--|-----|

|                              |  |     |
|------------------------------|--|-----|
| <b>Internet Access .....</b> |  | A14 |
|------------------------------|--|-----|

JCO Homepage .....

[www.jco.org](http://www.jco.org)

ASCO Online .....

[www.asco.org](http://www.asco.org)

 Online supplementary information  
Available at <http://www.jco.org>

# Immunohistochemistry Versus Microsatellite Instability Testing in Phenotyping Colorectal Tumors

By Noralane M. Lindor, Lawrence J. Burgart, Olga Leontovich, Richard M. Goldberg, Julie M. Cunningham, Daniel J. Sargent, Catherine Walsh-Vockley, Gloria M. Petersen, Michael D. Walsh, Barbara A. Leggett, Joanne P. Young, Melissa A. Barker, Jeremy R. Jass, John Hopper, Steve Gallinger, Bharati Bapat, Mark Redston, and Stephen N. Thibodeau for the Cooperative Family Registry for Colon Cancer Studies

**Purpose:** To compare microsatellite instability (MSI) testing with immunohistochemical (IHC) detection of *hMLH1* and *hMSH2* in colorectal cancer.

**Patients and Methods:** Colorectal cancers from 1,144 patients were assessed for DNA mismatch repair deficiency by two methods: MSI testing and IHC detection of *hMLH1* and *hMSH2* gene products. High-frequency MSI (MSI-H) was defined as more than 30% instability of at least five markers; low-level MSI (MSI-L) was defined as 1% to 29% of loci unstable.

**Results:** Of 1,144 tumors tested, 818 showed intact expression of *hMLH1* and *hMSH2*. Of these, 680 were microsatellite stable (MSS), 27 were MSI-H, and 111 were MSI-L. In all, 228 tumors showed absence of

*hMLH1* expression and 98 showed absence of *hMSH2* expression: all were MSI-H.

**Conclusion:** IHC in colorectal tumors for protein products *hMLH1* and *hMSH2* provides a rapid, cost-effective, sensitive (92.3%), and extremely specific (100%) method for screening for DNA mismatch repair defects. The predictive value of normal IHC for an MSS/MSI-L phenotype was 96.7%, and the predictive value of abnormal IHC was 100% for an MSI-H phenotype. Testing strategies must take into account acceptability of missing some cases of MSI-H tumors if only IHC is performed.

*J Clin Oncol* 20:1043-1048. © 2002 by American Society of Clinical Oncology.

IN THE NEAR FUTURE, there are likely to be important clinical indications for determining the molecular type of colorectal cancers (CRC). One parameter by which colorectal cancers can be classified involves alterations in the DNA mismatch repair process. Specifically, about 85% of CRC possess normal DNA mismatch repair function, whereas 15% have defective DNA mismatch repair. The latter category includes mostly sporadic tumors in which *hMLH1* promotor methylation has rendered the DNA mismatch repair complex incompetent. It also includes the cancers associated with hereditary nonpolyposis colon cancer syndrome (HNPCC)/Lynch syndrome that carry a germ-

line mutation in one of the DNA mismatch repair genes, usually *hMLH1* or *MSH2*.

The tumor phenotype associated with either hereditary or acquired loss of DNA mismatch repair competency is called microsatellite instability (MSI). MSI phenotypes have been subdivided into those with high (MSI-H) and low (MSI-L) levels of instability, with MSI-H usually defined as instability at  $\geq 30$  of loci studied, and MSI-L defined as instability at 1% to 29% of loci.<sup>1</sup> All other tumors are referred to as microsatellite stable (MSS). Uncertainty exists about the clinical and biologic significance of the MSI-L phenotype because, in most regards, the behavior of MSI-L tumors is similar to that of MSS tumors.

There is a growing body of evidence that there are clinical and histopathologic differences between MSI-H and MSS/MSI-L colorectal cancers. Tumors with an MSI-H phenotype are more likely to have mutations in genes with short repetitive tracts such as the transforming growth factor beta receptor gene, *BAX* genes, *IGF2R* gene, and others.<sup>2-7</sup> MSI-H tumors are less likely to have loss of *APC*,<sup>8-17</sup> or mutations in *p53*<sup>8,10,14-22</sup> or *K-ras*<sup>8-10,14-16,19,20,23-25</sup> compared with MSS tumors. MSI-H tumors are more likely to be diploid or nearly diploid,<sup>8,26-31</sup> Carcinoembryonic antigen expression is less common in MSI-H tumors.<sup>31</sup> MSI-H tumors more often arise in the right colon<sup>26,27,28,32</sup> and are more likely to occur in individuals with a positive family history of colorectal cancer.<sup>26,27</sup> A female predilection for MSI-H tumors has been noted,<sup>7,30,33</sup> and MSI-H tumors may have a better stage-specific prognosis.<sup>26,27</sup>

From the Departments of Medical Genetics, Laboratory Medicine and Pathology, Oncology, Biostatistics, and Clinical Epidemiology, Mayo Foundation, Rochester, MN; Pathology Department, University of Queensland, Queensland; Conjoint Gastroenterology Laboratory, Royal Brisbane Hospital, Brisbane; Department of General Practice and Public Health, University of Melbourne, Victoria, Australia; Departments of Surgery and Pathology, Mt Sinai Hospital, Toronto, Ontario, Canada; and Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Submitted July 20, 2001; accepted September 27, 2001.

Supported by National Institutes of Health UO1 grant nos. CA74800, CA74778, CA74783 (Cooperative Family Registry for Colon Cancer Studies), and CA68535.

Address reprint requests to Noralane M. Lindor, MD, E7B Medical Genetics, Mayo Clinic, 200 First St, SW, Rochester, MN 55905; email: nlindor@mayo.edu.

© 2002 by American Society of Clinical Oncology.

0732-183X/02/2004-1043/\$20.00

Additional differences are noted in the histopathologic examination. MSI-H tumors are more likely to show cribriform/solid growth pattern and signet ring histology or high-grade medullary histology<sup>28,30,31,34</sup> and to be mucinous<sup>30,35,36</sup> and exophytic.<sup>31</sup> MSI-H tumors may show enhanced immunologic response as determined by marked lymphocytic infiltration of the tumor.<sup>30,36</sup>

Experiments have recently shown in vitro differences in the response of MSI-H cell lines to chemotherapeutic agents. DNA mismatch repair-deficient cells are resistant to the alkylating agents melphalan and busulphan; the methylating agents procarbazine and temozolomide; the platinum-containing agents cisplatin and carboplatin; the antimetabolites 6-thioguanine, fluorouracil, and O<sup>6</sup>-methylguanine; and the topoisomerase inhibitors etoposide and doxorubicin (reviewed in<sup>37-39</sup>). The clinical significance of these observations remains unclear; however, one recent publication<sup>40</sup> described striking survival benefits in patients with right-sided colonic tumors who received adjuvant chemotherapy compared with those who did not. Little benefit from adjuvant therapy was noted in patients with left-sided tumors. Right-sided colon tumors are much more frequently MSI. The authors therefore suggest additional prospective studies on the predictive value of MSI regarding benefits from adjuvant chemotherapy. It does seem reasonable to suspect the potential for different susceptibilities to chemotherapeutic agents in MSS versus MSI-H tumors in light of the differences catalogued above.

Presently, determination of DNA mismatch repair competency status from CRC is offered in situations in which the diagnosis of HNPCC/Lynch syndrome is being considered; for example, in a proband with a positive family history of CRC or a very young individual with a diagnosis of CRC. As more is learned about differential responses to therapies between tumors with and without DNA mismatch repair competency, one must anticipate that testing will become even more widely conducted, perhaps encompassing all cases of newly diagnosed CRC in order to tailor therapeutic regimens to the biology of the colorectal tumor.

The current "gold standard" for assessing tumor DNA mismatch repair competency is molecular MSI testing. This is a labor-intensive test that involves extracting DNA from both tumor and normal tissue excised at surgery. The DNA is subjected to polymerase chain reaction (PCR) amplification of five or more different chromosomal loci that compare "microsatellites" (simple sequence repeat such as a CA dinucleotide repeat), running the PCR products through a gel to separate DNA fragments by size, comparing the tumor-normal pairs, and scoring for differences (MSI) between the two. Generally, instability at two or more out of five markers (or > 30% of markers tested) defines a tumor as MSI-H.

The intensive and time-consuming nature of this test is particularly clinically troublesome, because surgeons would frequently like to know preoperatively if a patient is likely to have HNPCC. This information might change the extent of the colectomy that is performed and lead to consideration for simultaneous hysterectomy and oophorectomy as well. The time frame from diagnosis to surgery is generally insufficient to allow tumor MSI results to be available at the time surgical decisions are being made.

It is known that in HNPCC, mutations in two of the DNA mismatch repair genes, known as *hMLH1* and *hMSH2*, account for about two thirds of families meeting Amsterdam criteria. However, in HNPCC patients with tumors with the MSI-H phenotype, nearly all families are thought to carry germline mutations in *hMLH1* or *hMSH2* (mutations in *hMSH6*, *hMSH3*, *hPMS2* are extremely uncommon). Furthermore, in sporadic tumors with MSI-H phenotype, a very high proportion of all tumors have methylation of the *hMLH1* promotor. Therefore, *hMLH1* or *hMSH2* are either mutated or methylated in the vast majority of MSI-H tumors identified to date. Monoclonal antibodies to the protein products of both *hMLH1* and *hMSH2* are now commercially available. This technique is far less labor intensive than traditional MSI testing, and the results can be available to inform clinical decisions within 24 hours.

We sought to determine the correlation between tumor MSI status and tumor IHC for the protein products of *hMLH1* and *hMSH2*, reasoning that if IHC was sufficiently sensitive and specific, tumor IHC might provide a rapid and cost-effective method for categorizing colorectal cancers into mismatch repair competency subgroups.

## PATIENTS AND METHODS

### *Patient/Tumor Ascertainment*

Tumors for this study came from a number of different sources. Three centers from the Cooperative Family Registry for Colon Cancer Studies (CFRs) participated in this study (additional information about the CFRs resource can be found at <http://www-dccps.ims.ncl.nih.gov/cfrccs/q&a.html>). Patients from the Mayo CFR site were recruited from three sources: (1) Mayo Clinic Rochester patients; (2) North Central Cancer Treatment Group patients, a consortium of community-based oncology practices throughout the middle United States; and (3) via the Minnesota Cancer Surveillance System, a population-based state cancer registry. Patients from the Australia CFR site were recruited from multiple family cancer clinics throughout Australia. Patients from the Ontario CFR site were recruited from a population-based cancer registry from throughout Ontario. All CFR sites had appropriate institutional review board review of protocols, and participants gave written informed consent for collection of blood and tumor tissue for use in cancer research. Patients completed extensive epidemiology questionnaires, family history was obtained, and additional affected and unaffected relatives were also invited to participate in the CFRs. The tumors from a variety of hospitals throughout the United States, Australia, and Canada were preserved in a variety of ways, and

Table 1. Summary of Patients Included in This Analysis

| Ascertainment Site                | No. of Cases | Age (years) |       |
|-----------------------------------|--------------|-------------|-------|
|                                   |              | Mean        | Range |
| Mayo CFR                          | 337          | 54          | 28-77 |
| Mayo CRA consecutive case series  | 255          | 69          | 29-91 |
| Australia CFR                     | 284          | 50          | 17-80 |
| Australia consecutive case series | 136          | 67          | 18-96 |
| Ontario CFR                       | 132          | NA          |       |
| Total                             | 1,144        |             |       |

tumor blocks varied in age from less than 1 year to more than 15 years since resection. The numbers and ages of patients in this study are listed in Table 1.

In addition, we pooled CFRs data with a series of unselected, consecutive cases of colorectal cancers resected at Mayo Clinic Rochester. These cases (hereafter called the Cancer Risk Assessment [CRA] cases) were obtained from 257 of 514 patients who underwent surgical resection during a 1.5-year period from December 1995 to April 1997 (57.2% of those approached did agree to participate) (Thibodeau et al, manuscript submitted for publication). There is no overlap with the CFRs cases. The male/female ratio was 1.47 (153 men, 104 women). For the nonparticipants ( $n = 199$ ), the male/female ratio was 1.1, indicating that male subjects were more likely to participate than female subjects. The nonparticipants were also older than the participants (median age, 72 v 69 years;  $P = .005$ ). Note that this aggregate data set is collected via oversampling of high-risk colon cancer probands, and thus is not suitable for determining such things as the frequency of MSI phenotypes in the general colon cancer population.

### DNA Extraction

DNA was extracted from frozen or paraffin-embedded tissues as described previously.<sup>33</sup> Briefly, DNA from microdissected frozen tissue sections (10  $\mu$ m) was extracted by a standard phenol/chloroform procedure. For tumor DNA, only those areas containing more than 70% tumor cells were used. For DNA extraction from paraffin-embedded tissues, the Qiamp tissue kit (Qiagen, Inc, Santa Clarita, CA) was used according to the manufacturer's instructions. The corresponding normal control DNA for each patient was derived from peripheral blood. For these specimens, DNA was extracted using the Puregene nucleic acid isolation kit (Gentra Systems, Minneapolis, MN).

### MSI

For the CFRs tumors, paired normal and tumor DNA was analyzed for MSI with 10 markers: mononucleotide markers BAT25, BAT26, BAT40, BAT34C4; dinucleotide markers D5S346, D17S250, ACTC, D18S55, and D10S197; and penta-mono-tetra compound marker MYCL.

For the CRA group, paired normal and tumor DNA were analyzed for MSI with six dinucleotide microsatellite markers (D5S346, TP53, D18S34, D18S49, D18S61, and ACTC) and one mononucleotide repeat (BAT 26). PCR and gel electrophoresis were carried out as described by Thibodeau et al.<sup>26</sup> Tumors were classified as MSI-H if  $\geq 30\%$  markers demonstrated instability, MSI-L if  $< 30\%$  demonstrated MSI, and MSS if no marker exhibited MSI.<sup>1,33</sup>

### Immunohistochemical Analysis

For immunohistochemical (IHC) analysis performed at the Mayo Clinic, tissue sections were cut at 6  $\mu$ m and mounted on Probe On

charged slides (Fisher Scientific, Pittsburgh, PA). After deparaffinization, slides were steam pretreated in EDTA buffer, pH 8.0, in a Black & Decker Handy Steamer Plus (Black & Decker, Shelton, CT) for 30 minutes. After rinsing in cool water, slides were loaded onto the Tech Mate 500 (Ventana Medical Systems, Tuscon, AZ) automated immunohistochemical stainer. The stainer uses capillary gap technology as the primary mode of operation. In order for successful staining performance, a gap measuring between 75 and 200  $\mu$ m must be formed between two slides where the tissues are face to face.

Staining is performed using an avidin-biotin complex methodology, supplied in kit form from Ventana Medical Systems (Biotek Solutions buffer kit, Biotek Solutions DAB detection kit). This test uses a primary antibody against *hMLH1* (clone G168-728, 1/250; Pharmingen, San Diego, CA) and *hMSH2* (clone FE11, 1/50; Oncogene Research Products, Cambridge, MA) that has been titrated on colon cancer sections and also tested on various normal and pathologic tissue specimens.

IHC in Australia used 4- $\mu$ m sections that were affixed to Superfrost Plus adhesive slides (Fisher Chemical Co, Pittsburgh, PA) and air-dried overnight at 37°C. Antigen retrieval was performed in 0.001 mol/L EDTA, pH 8.0, in an autoclave on "wet" cycle for 30 minutes. The sections were cooled in EDTA buffer for 20 minutes before being transferred to tris-buffered saline (TBS) (pH 7.4). Endogenous peroxidase activity was blocked by immersing the slides in 1.0%  $H_2O_2$ , 0.1%  $NaN_3$  in TBS for 10 minutes. Nonspecific antibody binding was inhibited by incubating the sections in 4% commercial nonfat skim milk powder in TBS for 15 minutes; then, after a brief rinse in TBS, the slides were transferred to a humidified chamber and incubated with 10% nonimmune normal goat serum. Excess nonimmune serum was decanted from the slides and sections were incubated with primary antibody overnight at room temperature. The primary antibodies used were *MLH1*, clone G168-15 (BD PharMingen, Franklin Lakes, NJ) 1/75; and *MSH2*, clone G219-1129 (PharMingen), 1/150.

The sections were washed in TBS and then transferred to a Shandon Sequenza staining system (Thermo-Trace, Noble Park, VIC, Australia). To block endogenous biotin-like activity unmasked by the antigen retrieval step, the slides were subjected to biotin blocking using the Dako Biotin Blocking kit (Dako, Carpinteria, CA) according to the manufacturer's instructions. The sections were incubated with biotinylated goat antimouse immunoglobulins (Jackson ImmunoResearch, West Grove, PA), diluted 1/250 in TBS for 45 minutes, then with streptavidin-horseradish peroxidase conjugate (Jackson ImmunoResearch) diluted 1/500 in TBS for 15 minutes. Antigenic sites were identified using 0.05% 3,3'-diaminobenzidine with  $H_2O_2$  as substrate, and were then lightly counterstained with Mayer's hematoxylin before being permanently mounted using DePeX (BDH-Gurr, Poole, United Kingdom).

### Statistical Methods

Sensitivity and specificity for IHC classification for MSI-H status was defined using the MSI results as the gold standard. Exact 95% confidence intervals (CIs) were calculated using the binomial distribution. Sensitivity was defined as the absence of *hMLH1* and *hMSH2* expression by IHC in MSI-H tumors. Specificity was defined as intact expression of *hMLH1* and *hMSH2* by IHC in MSS or MSI-L tumors.

### RESULTS

Of the 1,144 cases examined, 350 (30.6%) were classified as MSI-H by MSI testing. Of these, 323 showed absence of either *hMLH1* (70.6%) or *hMSH2* (29.4%) expression by

Table 2. Comparison of Colorectal Cancer IHC Results With MSI Results by Center

|                                | No. of Tumors With Intact Expression of <i>MLH1</i> and <i>MSH2</i> by IHC |     |     |    |     | No. of Tumors With Absent Expression of <i>MLH1</i> by IHC |    |     |    |     | No. of Tumors With Absent Expression of <i>MSH2</i> by IHC |   |    |    |    |
|--------------------------------|----------------------------------------------------------------------------|-----|-----|----|-----|------------------------------------------------------------|----|-----|----|-----|------------------------------------------------------------|---|----|----|----|
|                                | A                                                                          | B   | C   | D  | Σ   | A                                                          | B  | C   | D  | Σ   | A                                                          | B | C  | D  | Σ  |
| Total no. of cases (N = 1,144) | 274                                                                        | 204 | 251 | 89 | 818 | 41                                                         | 48 | 116 | 23 | 228 | 22                                                         | 3 | 53 | 20 | 98 |
| No. of MSS                     | 215                                                                        | 186 | 199 | 80 |     | 0                                                          | 0  | 0   | 0  |     | 0                                                          | 0 | 3* | 0  |    |
| No. of MSI-H                   | 12                                                                         | 0   | 8   | 7  |     | 41                                                         | 48 | 116 | 23 |     | 22                                                         | 3 | 50 | 20 |    |
| No. of MSI-L                   | 47                                                                         | 18  | 44  | 2  |     | 0                                                          | 0  | 0   | 0  |     | 0                                                          | 0 | 0  | 0  |    |

NOTE. Patient populations were not comparable across centers. The cases in B were not selected for high-risk findings and the cases in C had the highest risk profiles for hereditary cancers. This study does address incidence of MSI-H phenotype and should not be used for this purpose.

Abbreviations: A, Mayo CFR cases; B, Mayo CRA cases; C, Australian cases; D, Ontario cases; Σ, total for each category; MSS, all tested microsatellites were stable; MSI-H,  $\geq 30\%$  or more of microsatellites tested were unstable; MSI-L, 1-29% of tested microsatellites were unstable.

\*These three cases would not have been reported clinically as MSS because there was insufficient tumor burden in the postirradiated specimens to perform MSI testing reliably, and are included here only to highlight this technical issue in MSI testing. Germline mutations in *hMSH2* were present in the families of these three cases.

IHC, for a sensitivity of 92.3% (95% CI, 88.9% to 94.9%). Of the 794 cases found to be MSS or MSI-L by MSI testing, 794 (100%) showed normal IHC expression of both proteins, for a specificity of 100% (95% CI, 99.5% to 100%). The observed predictive value of absence of expression of either *hMLH1* or *hMSH2* (no cases showed absence of both) for predicting MSI-H status was 100%. The predictive value of normal expression of both of these proteins for predicting MSS/MSI-L status was 96.7%. Results of testing of 1,144 colorectal cancers for MSI testing and IHC for *hMLH1/hMSH2* are listed in Table 2.

## DISCUSSION

This comparative study provided an opportunity to assess the strengths and weaknesses of tumor MSI testing versus tumor IHC for determining the competence of the mismatch repair mechanism of tumors. Our interest was to determine the correlation between IHC and MSI, not in how to best diagnose HNPCC, nor were we trying to determine frequency of MSI in CRCs. Overall, this study showed that absence of expression of *hMLH1* or *hMSH2* had a 100% specificity for predicting a tumor with MSI-H phenotype (302 of 302). On the other hand, an MSI-H phenotype was present in 3.3% of tumors with normal expression of both *hMLH1* and *hMSH2* (27 of 818 tumors). The sensitivity of IHC for detecting MSI-H tumors was 92.3%. That is, 326 of 353 tumors with MSI-H phenotype had absence of expression of either *hMLH1* or *hMSH2*. Thus, in this mixed patient population that is oversampled for high-risk factors (young age, positive family history), an abnormal IHC test has a 100% predictive value for an MSI-H tumor phenotype, and a normal IHC test for these two proteins has a 96.7% predictive value for an MSS/MSI-L phenotype.

Others have looked at the issue of IHC versus MSI in smaller series in different populations for different reasons. Two groups have found 100% correspondence between tumor

MSI results and tumor IHC. Dieumegard et al<sup>41</sup> reported that 15 MSI-H tumors they studied had lack of expression of either *hMSH2* or *hMLH1* in each case, whereas normal expression was found in 17 MSS tumors. Cawkwell et al<sup>42</sup> studied 502 colorectal cancers. Sixty-six showed an MSI-H phenotype and all (100%) were associated with complete lack of expression of either *hMSH2* or *hMLH1*.

On the other hand, other groups have found less than 100% correspondence between these technologies. Debniak et al<sup>43</sup> studied 168 patients with CRC including 25 with suspected or known HNPCC. In this study, IHC was normal in 9% of cases (four of 43) in which an MSI-H tumor phenotype was found. Marcus et al<sup>44</sup> studied the expression of *hMLH1* and *hMSH2* in 72 formalin-fixed, paraffin-embedded tumors. MSI-H phenotype was predicted correctly in 37 of 38 tumors (97%). IHC expression was normal in all tumors without instability (34 of 34). Terdiman et al<sup>45</sup> used IHC on 38 MSI-H tumors, and four tumors (10.5%) had normal IHC (five were equivocal). Chaves et al<sup>46</sup> studied 76 cases of sporadic CRC and found MSI-H phenotype in nine cases; IHC detected only 75% of these. Ward et al<sup>47</sup> studied 308 colon tumors and found that 27 of 33 (82%) of MSI-H tumors had loss of *hMLH1* or *hMSH2*.

Tumor *hMLH1/hMSH2* IHC has many clear advantages over tumor MSI testing. If test costs are set according to actual workload, IHC will be much less expensive than MSI testing, and IHC can be performed more rapidly. Debniak et al<sup>43</sup> estimate that IHC costs only 14% to 28% of what MSI testing costs. On the basis of our experience, using workload recordings, we would agree with this estimate. Another substantial advantage of tumor IHC over MSI testing is that IHC outcome will guide clinicians to the correct gene for genetic testing in individuals/families in which the issue of HNPCC is under investigation. That is, absence of expression of either *hMLH1* or *hMSH2* indicates which gene is likely involved in an HNPCC family. Additionally, tumor IHC can be conducted on tiny tumor fragments such as those typically obtained from a

needle or colonoscopic biopsy. This type of fragment would frequently yield insufficient DNA to conduct MSI testing.

Are there differences in the likelihood of achieving a technically satisfactory test result between IHC or MSI testing? We did not systematically collect all the data required to answer this question, but made some observations as the data were collected. First, there may be a higher success rate for all testing using fresh tissue compared with archived tissues. With the CRA study, which used fresh frozen tissues, there were no technical failures for either MSI or IHC. With the Mayo CFR archival collection, we observed seven tumors in which MSI testing was technically unsuccessful (amplified in only one or two of the 10 attempted markers), but tumor IHC was successful in six of these cases. This included two cases with absence of *hMLH1* expression and two cases with absence of *hMSH2* expression. Alternatively, there were also two cases in which IHC failed but MSI was successful. Additional prospective studies are needed to look systematically at success rates between these two tests.

If the MSI status was determined solely on the basis of the IHC surrogate, what would IHC of *hMLH1/hMSH2* be expected to miss? Tumor MSI is a reflection of DNA mismatch repair function. Two hits to any of the other components of the DNA mismatch repair system (eg, *hMSH6*, *hPMS2*) can cause MSI-H tumor phenotype that would not be predicted by looking only at *hMLH1/hMSH2* IHC. In addition, it is possible that missense mutations in *hMLH1/hMSH2* may exist that transcribe and translate a stable but nonfunctional immunoreactive protein. This would give an apparently normal IHC. Among the discordant cases at Mayo and in Australia, preliminary work indicates that at least some of these cases are because of inactivation of *hMSH6* and *hPMS2*, although some cases remain unexplained.

Note also that in the three Australian cases with absent expression of *hMSH2* but no MSI, all three were rectal cancer cases that had been irradiated before resection. The very few tumor cells that were present in the specimen (estimated as < 3%) were not enough to yield an MSI-H phenotype, but were sufficient to be detected as islands of *hMSH2* deficient tumor cells by IHC. This MSI result would not have been reported clinically because it was apparent that the specimen was not suitable for reliable MSI testing. For the CFRs, sections with more than 70% tumor are generally used. It is clear that discrepant IHC/MSI results should prompt a search for a biologic/clinical/technical explanation for this finding and not just assume one test is "wrong."

What threshold for test sensitivity is acceptable for categorizing colorectal tumors as DNA mismatch repair proficient or not? The answer to that question surely depends on why the test is being ordered. If the goal is to identify HNPCC kindreds for making a rapid surgical decision or in offering genetic mutation analysis, that is different from categorizing for purposes of tailoring potential chemotherapy. IHC appears to offer a faster and less expensive alternative to MSI testing for classifying colorectal cancers by mismatch repair competency with essentially 100% specificity and greater than 92% sensitivity. Clinicians must decide on a case-by-case basis if they are comfortable with the predictive value of the IHC testing for a particular patient. This weighting may shift if the utility of colorectal tumor phenotyping becomes more important in informing treatment decisions.

#### ACKNOWLEDGMENT

We thank all the patients and family members who participated in this study.

#### REFERENCES

1. Boland CR, Thibodeau SN, Hamilton SR, et al: A National Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer. *Cancer Res* 58:5248-5257, 1998
2. Markowitz S, Wang J, Myeroff L, et al: Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. *Science* 268:1336-1338, 1995
3. Wang J, Sun LA, Myeroff L, et al: Demonstration that mutation of the type II transforming growth factor beta receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells. *J Biol Chem* 270:22044-22049, 1995
4. Souza RF, Appel R, Yin J, et al: The insulin-like growth factor II receptor gene is a target of microsatellite instability in human gastrointestinal tumors. *Nat Genet* 14:255-257, 1996
5. Rampino N, Yamamoto H, Ionov Y, et al: Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. *Science* 275:967-969, 1997
6. Oliveria C, Seruca R, Seizas M, et al: The clinicopathological features of gastric carcinomas with microsatellite instability may be mediated by mutations of different "target genes": A study of the TGFbetaRII, IGFIIR, and BAX genes. *Am J Pathol* 153:1211-1219, 1998
7. Planck M, Wenngren E, Borg A, et al: Somatic frameshift alteration in mononucleotide repeat-containing genes in different tumor types from an HNPCC family with germline MSH2 mutation. *Genes Chromosom Cancer* 29:33-39, 2000
8. Aaltonen LA, Peltomaki P, Leach FS, et al: Clues to the pathogenesis of familial colorectal cancer. *Science* 260:812-816, 1993
9. Heinen CD, Richardson D, White R, et al: Microsatellite instability in colorectal adenocarcinoma cell lines that have full-length adenomatous polyposis coli protein. *Cancer Res* 55:4797-4799, 1995
10. Konishi M, Kikuchi-Yanoshita R, Tanaka K, et al: Molecular nature of colon tumors in hereditary nonpolyposis colon cancer, familial polyposis, and sporadic colon cancer. *Gastroenterology* 111:307-317, 1996

11. Huang J, Papadopoulos N, McKinley AJ, et al: APC mutations in colorectal tumors with mismatch repair deficiency. *Proc Natl Acad Sci U S A* 93:9049-9054, 1996
12. Bocker T, Schlegel J, Kullman F, et al: Genomic instability in colorectal carcinomas: Comparison of different evaluation methods and their biological significance. *J Pathol* 179:15-19, 1996
13. Muta H, Noguchi M, Perucho M, et al: Clinical implications of microsatellite instability in colorectal cancer. *Cancer* 77:265-270, 1996
14. Olschwang S, Hamelin R, Laurent-Puig P, et al: Alternative genetic pathways in colorectal carcinogenesis. *Proc Natl Acad Sci U S A* 94:12122-12127, 1997
15. Salahshor S, Kressner U, Pahlman L, et al: Colorectal cancer with and without microsatellite instability involves different genes. *Genes Chromosom Cancer* 26:247-252, 1999
16. Shitoh K, Konishi F, Miyaki M, et al: Pathogenesis of non-familial colorectal carcinomas with high microsatellite instability. *J Clin Pathol* 53:841-845, 2000
17. Cottu PH, Muzeau F, Estreicher A, et al: Inverse correlation between RER+ status and p53 mutation in colorectal cancer cell lines. *Oncogene* 13:2727-2730, 1996
18. Ionov Y, Peinado MA, Malkhosyan S, et al: Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. *Nature* 363:558-561, 1993
19. Losi L, Ponz de Leon M, Jiricny J, et al: K-ras and p53 mutations in hereditary non-polyposis colorectal cancers. *Int J Cancer* 74:94-96, 1997
20. Tsuchiya A, Nomizu T, Onda M, et al: Molecular genetic alteration and DNA ploidy in hereditary nonpolyposis colorectal cancer. *Int J Clin Oncol* 2:224-229, 1997
21. Simms LA, Radford-Smith G, Biden KG, et al: Reciprocal relationship between the tumor suppressors p53 and BAX in primary colorectal cancers. *Oncogene* 17:2003-2008, 1998
22. Iacopetta BJ, Welch J, Soong R, et al: Mutation of the transforming growth factor-beta type II receptor gene in right-sided colorectal cancer: Relationship to clinicopathological features and genetic alterations. *J Pathol* 184:390-395, 1998
23. Fujiwara T, Stoker JM, Watanabe T, et al: Accumulated clonal genetic alterations in familial and sporadic colorectal carcinomas with widespread instability in microsatellite sequences. *Am J Pathol* 153:1063-1078, 1998
24. Jass JR, Biden KG, Cummings M, et al: Characterization of a subtype of colorectal cancer combining features of the suppressor and mild mutator pathways. *J Clin Pathol* 52:455-460, 1999
25. Slattery ML, Curtin K, Anderson K, et al: Associations between cigarette smoking, lifestyle factors, and microsatellite instability in colon tumors. *J Natl Cancer Inst* 92:1831-1836, 2000
26. Thibodeau SN, Bren G, Schaid D: Microsatellite instability in cancer of the proximal colon. *Science* 260:816-819, 1993
27. Lothe RA, Peltomaki P, Meling GI, et al: Genomic instability in colorectal cancer: Relationship to clinicopathological variables and family history. *Cancer Res* 53:5849-5952, 1993
28. Bubb VJ, Curtis LJ, Cunningham G, et al: Microsatellite instability and the role of hMSH2 in sporadic colorectal cancer. *Oncogene* 12:2641-2649, 1996
29. Brassett C, Joyce JA, Froggatt NJ, et al: Microsatellite instability in early onset and familial colorectal cancer. *J Med Genet* 33:981-985, 1996
30. Risio M, Reato G, diCelle PF, et al: Microsatellite instability is associated with the histological features of the tumor in nonfamilial colorectal cancer. *Cancer Res* 56:5470-5474, 1996
31. Kim H, Jung JK, Park JH, et al: Immunohistochemical characteristics of colorectal carcinoma with DNA replication error. *J Korean Med Sci* 11:137-143, 1996
32. Senba S, Konishi F, Okamoto T, et al: Clinicopathologic and genetic features of nonfamilial colorectal carcinomas with DNA replication errors. *Cancer* 82:279-285, 1998
33. Thibodeau SN, French AJ, Cunningham JM, et al: Microsatellite instability in colorectal cancer: Different mutator phenotypes and the principal involvement of hMLH1. *Cancer Res* 58:1713-1718, 1998
34. Krishna M, Burgart LJ, French AJ, et al: Predictive value of histopathology for mutator phenotype (microsatellite instability) in colorectal carcinoma. *Gastroenterology* 112:4595, 1997 (abstr)
35. Messerini L, Vitelli F, Devitis LR, et al: Microsatellite instability in sporadic mucinous colorectal carcinomas: Relationship to clinico-pathological variables. *J Pathol* 182:380-384, 1997
36. Jass JR, Do K-A, Simms LA, et al: Morphology of sporadic colorectal cancer with DNA replication errors. *Gut* 42:673-679, 1998
37. Anthony DA, McIlwrath AJ, Gallagher WM, et al: Microsatellite instability, apoptosis, and the loss of p53 function in drug-resistant tumor cells. *Cancer Res* 56:1374-1381, 1996
38. Rodriguez-Bigas MA, Vasen HFA, Pekka-Mecklin J, et al: Rectal cancer risk in hereditary nonpolyposis colorectal cancer after abdominal colectomy. *Ann Surg* 225:202-207, 1997
39. Fink D, Aebi S, Howell SB: The role of DNA mismatch repair in drug resistance. *Clin Cancer Res* 4:1-6, 1998
40. Elsaleh H, Joseph D, Griew F, et al: Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. *Lancet* 335:1745-1750, 2000
41. Dieumegard B, Grandjouan S, Sabourin JC, et al: Extensive screening for hereditary non-polyposis colorectal cancer. *Br J Cancer* 82:871-880, 2000
42. Cawkwell L, Gray S, Murgatroyd H, et al: Choice of management strategy for colorectal cancer based on a diagnostic immunohistochemical test for defective mismatch repair. *Gut* 45:409-415, 1999
43. Debniak T, Kurzawski G, Gorski B, et al: Value of pedigree/clinical data, immunohistochemistry and microsatellite instability analyses in reducing the cost of determining hMLH1 and hMSH2 gene mutations in patients with colorectal cancer. *Eur J Cancer* 36:49-54, 2000
44. Marcus VA, Madlensky L, Gryfe R, et al: Immunohistochemistry for hMLH1 and hMSH2: A practical test for DNA mismatch repair-deficient tumors. *Am J Surg Pathol* 23:1248-1255, 1999
45. Terdiman JP, Gum JR, Conrad PG, et al: Efficient detection of hereditary nonpolyposis colorectal cancer gene carriers by screening for tumor microsatellite instability before germline genetic testing. *Gastroenterology* 120:21-30, 2001
46. Chaves P, Cruz C, Lage P, et al: Immunohistochemical detection of mismatch repair gene proteins as a useful tool for the identification of colorectal carcinoma with the mutator phenotype. *J Pathol* 191:355-360, 2000
47. Ward R, Meagher A, Tomlinson I, et al: Microsatellite instability and the clinicopathological features of sporadic colorectal cancer. *Gut* 48:821-829, 2001